• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human C3 and PZP-like alpha-2-macroglobulin domain-containing protein 8 (CPAMD8), Truncated

ACP15079

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP15079 Target NameCPAMD8
Target SynonymsC3 and PZP-like alpha-2-macroglobulin domain-containing protein 8; CPAMD8; CPMD8_HUMAN; K CAP; VIPFormLyophilized powder
Expression SystemCustom Production. Please inquire and provide the desire expression system.Protein LengthPartial
Purity>85% (SDS-PAGE)Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDQ8IZJ3
Background Information
  • Uniprot Id

    Q8IZJ3

  • Target Species

    Human

  • Target Name

    CPAMD8

  • Target Full Name

    C3 and PZP-like alpha-2-macroglobulin domain-containing protein 8

  • Target Involvement

    Anterior segment dysgenesis 8 (ASGD8)

  • Target Subcellular Location

    Secreted. Cell membrane; Peripheral membrane protein; Extracellular side.

  • Target Protein Families

    Protease inhibitor I39 (alpha-2-macroglobulin) family

  • Target Tissue Specificity

    Highly expressed in the kidney, brain and testis and to a lower extent in heart, liver and small intestine. Expressed in the lens, cornea and retina. Strongly expressed in the distal tips of the retinal neuroepithelium that form the iris and ciliary body.

  • Target Synonyms

    C3 and PZP-like alpha-2-macroglobulin domain-containing protein 8; CPAMD8; CPMD8_HUMAN; K CAP; VIP

Inquire Recombinant Human C3 and PZP-like alpha-2-macroglobulin domain-containing protein 8 (CPAMD8), Truncated Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification